UK Markets close in 3 hrs 18 mins

Infinity Pharmaceuticals, Inc. (INFI)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
1.1800-0.0200 (-1.67%)
At close: 04:00PM EST
1.1800 0.00 (0.00%)
Pre-market: 07:32AM EST
Full screen
Trade prices are not sourced from all markets
Previous close1.2000
Open1.2500
Bid1.0800 x 1300
Ask1.3400 x 3000
Day's range1.1600 - 1.2800
52-week range1.0600 - 5.9800
Volume994,891
Avg. volume1,617,058
Market cap105.038M
Beta (5Y monthly)1.96
PE ratio (TTM)N/A
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
All
News
  • Business Wire

    Infinity Pharmaceuticals to Be Featured in a Fireside Chat as Part of B. Riley’s 2022 Virtual Oncology Conference

    CAMBRIDGE, Mass., January 20, 2022--Infinity Pharmaceuticals, Inc. (NASDAQ: INFI), a clinical-stage biotechnology company developing eganelisib, a first-in-class, oral, immuno-oncology macrophage reprogramming therapeutic, today announced that it will be highlighted during a virtual oncology fireside chat with B. Riley biotech research analyst Kalpit Patel on Thursday, January 27th at 10:30 am ET. The fireside chat will feature an interactive discussion with Infinity’s Executive Leadership Team,

  • Business Wire

    Infinity to Present at 40th Annual J.P. Morgan Healthcare Conference

    CAMBRIDGE, Mass., January 06, 2022--Infinity Pharmaceuticals, Inc. (NASDAQ: INFI), a clinical-stage biotechnology company developing eganelisib, a potentially first-in-class, oral, immuno-oncology macrophage reprogramming therapeutic, today announced that Adelene Perkins, Chief Executive Officer, will give a corporate presentation at 7:30am ET on January 13, 2022 at the 40th annual J.P. Morgan Healthcare Conference, taking place virtually.

  • Business Wire

    Infinity Pharmaceuticals Outlines Eganelisib Clinical Development Strategy and Provides 2022 Guidance

    CAMBRIDGE, Mass., January 05, 2022--Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) a clinical-stage biotechnology company developing eganelisib, a first-in-class, oral, immuno-oncology macrophage reprogramming therapeutic, today provided an update on eganelisib clinical development plans and 2022 guidance.